Research Analysts Offer Predictions for RDY FY2025 Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Stock analysts at Zacks Research raised their FY2025 earnings per share estimates for shares of Dr. Reddy’s Laboratories in a research note issued to investors on Tuesday, November 26th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.81 per share for the year, up from their prior forecast of $0.80. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.83 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2025 earnings at $0.23 EPS, Q1 2026 earnings at $0.20 EPS, Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.84 EPS, Q1 2027 earnings at $0.18 EPS and Q2 2027 earnings at $0.16 EPS.

A number of other analysts have also commented on RDY. StockNews.com lowered Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 13th. Barclays decreased their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY stock opened at $14.08 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92. Dr. Reddy’s Laboratories has a fifty-two week low of $12.90 and a fifty-two week high of $16.89. The firm has a market cap of $11.75 billion, a P/E ratio of 22.49 and a beta of 0.56. The business’s 50 day moving average price is $15.27 and its 200-day moving average price is $15.34.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. World Investment Advisors LLC purchased a new position in shares of Dr. Reddy’s Laboratories in the 3rd quarter valued at approximately $3,459,000. Virtu Financial LLC bought a new position in Dr. Reddy’s Laboratories in the third quarter worth $276,000. Geode Capital Management LLC lifted its position in Dr. Reddy’s Laboratories by 109.3% during the third quarter. Geode Capital Management LLC now owns 13,254 shares of the company’s stock valued at $1,053,000 after buying an additional 6,920 shares during the period. Public Employees Retirement System of Ohio purchased a new position in Dr. Reddy’s Laboratories during the third quarter valued at $464,000. Finally, EWA LLC purchased a new stake in shares of Dr. Reddy’s Laboratories in the 3rd quarter worth about $899,000. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.